EcoDrugPlus

60s Ribosomal Protein L4-B-Like

Ensembl ID : ENSSLUG00000000272
Gene Symbol: LOC116038430
3 Cross references
341 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSSLUG00000005839
Gene Symbol: ARAF
3 Cross references
191 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSSLUG00000015925
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSSLUG00000012343
Gene Symbol: ADAM17
3 Cross references
208 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSSLUG00000018250
Gene Symbol: ADAM17
1 Cross references
210 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSSLUG00000014994
Gene Symbol: ADAMTS5
1 Cross references
199 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSSLUG00000017357
Gene Symbol: ADRM1
1 Cross references
191 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSSLUG00000003323
Gene Symbol: AKT1
3 Cross references
195 Possible Orthologues:

Apex Nuclease (Multifunctional Dna Repair Enzyme) 1

Ensembl ID : ENSSLUG00000006097
Gene Symbol: APEX1
1 Cross references
212 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSSLUG00000017340
Gene Symbol: ABCC1
1 Cross references
201 Possible Orthologues:

Atp-Binding Cassette, Sub-Family C (Cftr/mrp), Member 8

Ensembl ID : ENSSLUG00000001314
Gene Symbol: ABCC8
1 Cross references
225 Possible Orthologues:

Atp-Binding Cassette, Sub-Family C (Cftr/mrp), Member 9

Ensembl ID : ENSSLUG00000018578
Gene Symbol: ABCC9
1 Cross references
231 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).